Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart stem cell trial pulled before it even started

NCT ID NCT03902067

Disease control Sponsor: Shanghai Life Science & Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial aimed to test whether umbilical cord stem cells, delivered through a catheter into heart arteries, could safely improve heart function in people with severe heart damage after a major heart attack. It was designed for patients with very weak hearts (ejection fraction below 35%) and large scars. However, the study was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
umbilical cord mesenchymal stem cells (UC-MSC)

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Expected to start

Dec 2024

An estimate. Start dates often move.

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with acute extensive anterior myocardial infarction were successfully treated with emergency interventional therapy within 12 hours after onset. LVEF was less than 0.35 by echocardiography 30 days after operation, scar area was more than 25% by MRI, and cardiac function was NYHA III-IV grade. * Fully inform the purpose, method and possible side effects of the test, agree to the test, and sign an informed consent form; * Good compliance, willing to take drugs and follow up according to the requirements of the plan; * Life expectancy exceeds one year. Exclusion Criteria: * Those who cannot tolerate cell therapy; * Patients with severe hepatic and renal insufficiency (ALT\>1.5 times the upper limit of normal value, Cr \>1.5 times the upper limit of normal value); * Patients with malignant tumors or extremely weak patients; * Patients with severe infection; * Patients who are expected to have the second coronary intervention or bypass grafting within 3 months; * Patients with other serious systemic diseases and organ dysfunction; * Patients with cardiogenic shock; * Patients with hemorrhagic diseases; * Researchers believe that anyone who is not suitable for inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction left ventricular failure Ventricular Dysfunction, Left

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myocardial infarction Left ventricular dysfunction

Contacts and locations

Locations

  • Shanghai Jiao Tong University Affiliated Sixth People's Hospital

    Shanghai, Shanghai Municipality, 200233, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.